Exhibit 99.1

              Gene Logic Board Elects Two New Directors

    -- David Urdal of Dendreon and Mark Gabrielson of Pulmatrix Add
                       Significant Experience --

            -- Jules Blake, Ph.D., to Retire from Board --


    GAITHERSBURG, Md.--(BUSINESS WIRE)--April 11, 2007--Gene Logic
Inc. (NASDAQ:GLGC) announced today that the Company's Board of
Directors has elected David L. Urdal, Ph.D., of Dendreon Corporation
(NASDAQ:DNDN) and Mark J. Gabrielson of Pulmatrix Inc. as directors.

    David L. Urdal, Ph.D. is currently Senior Vice President and Chief
Scientific Officer of Dendreon Corporation, a Seattle-based
biotechnology company focused on the discovery, development and
commercialization of novel therapeutics that harness the immune system
to fight cancer. Dr. Urdal has served as Dendreon's Chief Scientific
Officer since joining the company in 1995. Prior to that time, he held
various positions with Immunex Corporation, including President of
Immunex Manufacturing Corporation, Vice President and Director of
Development, and head of the departments of biochemistry and membrane
biochemistry. Dr. Urdal received an M.S. in Public Health and a Ph.D.
in Biochemical Oncology from the University of Washington.

    Mark J. Gabrielson is a co-founder, director, and Chief Executive
Officer of Pulmatrix Inc., a Cambridge, Massachusetts developer of
proprietary aerosol inhalants designed to control respiratory
infectious disease. Mr. Gabrielson has twenty-eight years of
experience in pharmaceuticals and biopharmaceutical company formation
and development. Following graduation from Princeton University, he
held a sequence of commercial assignments over a twelve year period at
SmithKline Beecham. During the period 1990-1999, Mr. Gabrielson was a
General Partner of Prince Ventures LP, a private venture capital firm
specializing in healthcare investing. Subsequently, Mr. Gabrielson
co-founded and developed a series of emerging companies, including
Pulmatrix.

    Chairman of the Board J. Stark Thompson, Ph.D., said, "Our Gene
Logic Board welcomes both Dr. Urdal and Mr. Gabrielson
enthusiastically. Their skills and experience are highly complementary
to our Board talent set. Their insights will be of great value as Gene
Logic continues to execute its strategic plan. The other board members
and I welcome both gentlemen to Gene Logic and look forward to working
with them."

    Gene Logic also announced today that Dr. Jules Blake has elected
to retire from the Company's Board of Directors. Dr. Blake has been a
Gene Logic Board Director since the Company's original formation in
1994.

    Chairman of the Board J. Stark Thompson, Ph.D., said, "The Board
of Directors recognizes Dr. Blake's significant contributions to Gene
Logic throughout the early stages of the Company's development and
thanks him for his dedicated service over this sustained period of
time."

    Gene Logic Overview

    Gene Logic is transforming into a biopharmaceutical development
company through partnerships with pharmaceutical companies. Our
partners provide Gene Logic with access to their drug candidates that
have been assessed as safe in human clinical trials but discontinued
for other reasons. Gene Logic applies its drug indication platform to
find new therapeutic uses for the drug candidates. Gene Logic expects
to receive milestone payments and royalties on drug candidates that
our partners choose to develop based on the indications we find or, if
the partner elects not to pursue such new indications, Gene Logic may
receive ownership and development rights.

    Gene Logic has also developed proprietary genomics databases and
services to enable customers worldwide to discover and prioritize drug
targets, identify biomarkers, predict toxicity and understand
mechanisms of toxicity, and obtain insights into the efficacy of
specific compounds. We continue to offer customers these services and
licenses to the databases. Such databases, services and expertise are
also a vital part of our drug indication platform. We are now seeking
strategic alternatives to use our Genomics assets capabilities and
expertise for molecular diagnostics.

    Founded in 1994, Gene Logic is headquartered in Gaithersburg, Md.,
with additional research and development facilities in Cambridge,
Mass. The Company currently has about 150 employees worldwide. For
more information, visit www.genelogic.com or call toll-free -
1/800/GENELOGIC.

    Safe Harbor Statement

    This press release contains "forward-looking statements," as such
term is used in the Securities Exchange Act of 1934, as amended. Such
forward-looking statements include the Company's ability to identify
strategies for making its businesses successful and the impact of such
strategies on our business and financial performance and on
shareholder value. Forward-looking statements typically include the
words "expect," "anticipate," "believe," "estimate," "intend," "may,"
"will," and similar expressions as they relate to Gene Logic or its
management. Forward-looking statements are based on our current
expectations and assumptions, which are subject to risks and
uncertainties. They are not guarantees of our future performance or
results. Our actual performance and results could differ materially
from what we project in forward-looking statements for a variety of
reasons and circumstances, including particularly such risks and
uncertainties that may affect the Company's operations, financial
condition and financial results and that are discussed in detail in
the Company's Annual Report on Form 10-K and our other subsequent
filings with the Securities and Exchange Commission. They include, but
are not limited to: whether we will be able to identify and
successfully implement strategies, on favorable terms or at all, for
improving the performance and value of our businesses and improving
the value of our Genomics business and whether repositioned compounds
are successfully returned to our customers' pipelines and generate
sales, and resulting milestones and royalties for the Company or
whether we acquire repositioned compounds on acceptable terms and are
able to derive revenue from these compounds through licensing or
otherwise, whether we can enter into agreements to develop sufficient
compounds to fulfill our plans for the Drug Repositioning Division,
and improving the value of our businesses to shareholders; whether
there will be remaining price adjustments or liabilities associated
with the sale of the Pre-Clinical Division, whether we will be able
successfully to manage our existing cash adequately and whether we
will have access to financing on sufficiently favorable terms to
maintain our businesses and effect our strategies, including
development of repositioned compounds; whether we will be able to
recruit and retain qualified personnel, particularly in light of our
restructuring efforts; potential negative effects on our operations
and financial results from workforce reductions, other restructuring
activities, and the evaluation of strategic options; the potential
loss of significant customers; the possibility of further write-down
of the value of certain intangible assets of the Company, including
goodwill associated with the Genomics Division; and the possibility of
delisting from NASDAQ Global Markets, which could have an adverse
effect on the value of our stock. Gene Logic undertakes no obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.

    CONTACT: Gene Logic Inc., Gaithersburg
             Investors:
             Philip L. Rohrer, Jr., 301-987-1700
             Email: prohrer@genelogic.com
             or
             Investors and Media:
             Christopher Culotta, 301-987-1752
             Email: cculotta@genelogic.com